|
|
|
| Clinical effect of topical Nocardia rubra cell wall skeleton in the treatment of persistent high-risk HPV infection of the cervix |
| HUANG Hongxiang GU Jianquan YAN Hongchao |
| Department of Gynecology and Obstetrics, Affiliated Hospital of Xuzhou Medical University, Jiangsu Province, Xuzhou 221000, China |
|
|
|
Abstract Objective To explore clinical effect of topical Nocardia rubra cell wall skeletal (Nr-CWS) in the treatment of cervical high-risk human papillomavirus (HPV) infection. Methods All of 273 cervical high-risk HPV patients admitted to Affiliated Hospital of Xuzhou Medical University from June 2018 to January 2020 were collected, they were divided into observation group (n = 136) and control group (n = 137). Observation group was treated with Nr-CWS, while control group was treated with recombinant human interferon α-2b gel. Clinical efficacy after treatment of three months and six months and adverse reactions during treatment were compared between two groups. Results Total effective rate of observation group after treatment of three months and six months was significantly higher than that of control group (P < 0.05). There was no significant difference in total effective rate between single subtype infection subgroup and multiple subtype infection subgroup (P > 0.05). Total effective rate of HPV-16 subgroup, HPV-16 with other subgroups, HPV-18 with other subgroups, HPV-18 with HPV-16 subgroups, HPV-18 with HPV-16 subgroups, single other high-risk subtype subgroups and multiple other high-risk subtype subgroups were higher than those of HPV-18 subgroup (P < 0.05). Total effective rates of HPV-16 subgroup, HPV-16 with other subgroups, HPV-18 with other subgroups, HPV-18 with HPV-16 subgroups and HPV-18 with HPV-16 and other subgroups were higher than those of single other high-risk subtype subgroups and multiple other high-risk subgroups (P < 0.05). There was no significant difference in the incidence rate of adverse reaction between two groups during treatment (P > 0.05). Conclusion The efficacy of topical Nr-CWS in the treatment of cervical high-risk HPV infection is better than that of recombinant human interferon α-2b gel, which is worthy of clinical promotion.
|
|
|
|
|
|
[1] Scheller NM，Pasternak B，M?覬lgaard-Nielsen D，et al. Quadrivalent HPV vaccination and the risk of adverse pregnancy outcomes [J]. N Engl J Med，2017，376（13）：1223-1233.
[2] 何玥，阴赪宏，赵群，等.人乳头瘤病毒（HPV）感染患者的管理现状[J].中国妇产科临床杂志，2017，18（1）：87-89.
[3] Chabeda A，Yanez RJR，Lamprecht R，et al. Therapeutic vaccines for high-risk HPV-associated diseases [J]. Papillomavirus Res，2018，5：46-58.
[4] 薛春芬，韩延霞，陈莲萍.重组人干扰素α-2b凝胶联合微波治疗HPV病毒感染合并宫颈柱状上皮异位的疗效观察[J].中国妇幼保健，2019，34（2）：452-455．
[5] Dzyublyk I，Yegorova T，Moroz L，et al. Controlled release recombinant human interferon-α2b for treating patients with chronic hepatitis C genotype 1：a phase 2a clinical trial [J]. J Viral Hepat，2011，18（4）：271-279.
[6] Abdolvahab MH，Fazeli A，Halim A，et al. Immunogenicity of recombinant human interferon α-2b in immune-tolerant transgenic mice corresponds with the biophysical characteristics of aggregates [J]. J Interferon Cytokine Res，2016，36（4）：247-257.
[7] 陈敏，何燕燕，陈云芳.激光联合重组人干扰素α2b凝胶治疗尖锐湿疣的临床研究[J].中国性科学，2016，25（6）：90-92.
[8] 于淼淼，杨露.抗妇炎胶囊联合重组人干扰素α2b对慢性宫颈炎伴HPV感染患者的临床疗效[J].中成药，2020， 42（1）：89-93.
[9] 赵东婷，韩萍.药物治疗对高危型人乳头瘤病毒感染的转归及白细胞介素-4变化的研究[J].中国计划生育和妇产科，2018，10（6）：31-34．
[10] 蒋晓蓉，孟以秀，彭玲.重组人干扰素α2b治疗宫颈糜烂合并人乳头瘤病毒感染的临床观察[J].中国药房，2017， 28（3）：331-334.
[11] 朱婷，陈蓓蓓.一种专用皮肤黏膜消毒剂治疗高危型人乳头瘤病毒持续感染患者的疗效及安全性[J].解放军预防医学杂志，2019，37（8）：71-72.
[12] 苏小玉，蒙莉萍，邹聪聪，等.重组人干扰素凝胶联合保妇康栓治疗宫颈高危型HPV感染的临床观察[J].中国药房，2020，31（8）：984-988.
[13] Bruni L，Diaz M，Castellsagué X，et al. Cervical human papillomavirus prevalence in 5 continents：meta-analysis of 1 million women with normal cytological findings [J]. J Infect Dis，2010，202（12）：1789-1799.
[14] 金玉，金华，张同一，等.妊娠期HPV病毒感染和宫颈鳞状上皮内瘤变的相关性研究[J].中华医院感染学杂志，2016，26（16）：3791-3793.
[15] 陈丽娟，强萍，陈萍，等.宫颈癌前病变伴HPV高危型感染患者膦甲酸钠氯化钠注射液治疗的效果研究[J].中华医院感染学杂志，2015，25（20）：4764-4766.
[16] 何鑫，陶绘丞，刘晨，等.医院机会性筛查人群HR-HPV感染的流行病学特征及与宫颈癌前病变的关系[J].首都医科大学学报，2015，36（2）：219-225.
[17] 章文华.重视子宫颈癌患者年轻化趋势[J].浙江肿瘤，2000，6（2）：112.
[18] Syrjanen S，Naud P，Sarian L，et al. Up-regulation of 14-3-3sigma（Stratifin）is associated with high-grade CIN and high-risk,human papillomavirus（HPV）at baseline but dose not predict outcomes of HR-HPV infections or incident CIN in the LAMS study [J]. Am J Clin Pathol，2010，133（2）：232-240.
[19] Venturoli S，Costa S，Barbieri D，et al. Time to viral clearance after successful conservative treatment for high-risk HPV-infected high-grade cervical intraepithelial neoplasia and early invasive squamous cervical carcinoma [J]. Diagn Microbiol Infect Dis，2016，86（3）：270-272.
[20] 徐红儿，饶慧，马美芬.宫颈高危型人乳头状瘤病毒感染保妇康栓治疗的临床研究[J].中华医院感染学杂志，2015，25（8）：1887-1889.
[21] Zhao J，Du HJ，Liao QP. Effect of nocardia rubra cell wall skeleton on the growth of hela cell line infected with HPV [J]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi，2007，21（1）：20-22.
[22] 王燕，张哲，何颖.诺卡菌细胞壁骨架胞比佳治疗癌性腹水例临床观察[J].中国医学理论与实践，2003，14（7）：912-913.
[23] Zlotta AR，Schulmn CC. Biological response modifier for the treatment of superficial bladder tumors [J]. Eur Urol，2000，37 Suppl 3：10-15.
[24] 李欢梓，李志玲，汪艳珠，等.红色诺卡氏菌细胞壁骨架治疗宫颈HPV亚临床感染的疗效评价[J].中国麻风皮肤病杂志，2012，28（3）：161-164.
[25] 潘梅钦，舒静，宋爱清，等.外用红色诺卡氏菌细胞壁骨架治疗HPV感染的疗效探讨[J].中外医疗，2019，38（4）：25-28. |
|
|
|
